Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
NHWD-870 by Ningbo Wenda Pharmaceutical Technology for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma): Likelihood of Approval
NHWD-870 is under clinical development by Ningbo Wenda Pharmaceutical Technology and currently in Phase II for NUT Midline Carcinoma (NMC...